심혈관 중재시술 기기 시장 : 규모, 점유율, 성장률 및 세계 업계 분석(유형 및 용도별), 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of interventional cardiology devices Market

The global interventional cardiology devices market was valued at USD 17.86 billion in 2025 and is projected to grow from USD 19.12 billion in 2026 to USD 34.01 billion by 2034, registering a CAGR of 7.50% during 2026-2034. North America dominated the global market with a 33.90% share in 2025, driven by the rising incidence of coronary heart diseases, favorable reimbursement frameworks, and continuous product innovations.

Interventional cardiology devices are specialized tools used in minimally invasive procedures to treat coronary artery disease (CAD), structural heart disorders, and other cardiovascular conditions. Devices such as coronary stents, angioplasty balloons, cutting balloon catheters, and Percutaneous Transluminal Coronary Angioplasty (PTCA) systems are widely used across hospitals and cardiac catheterization laboratories.

According to the World Health Organization, cardiovascular diseases (CVDs) account for approximately 17.9 million deaths globally each year, making them the leading cause of mortality worldwide. Additionally, the Centers for Disease Control and Prevention reported that around 20.1 million U.S. adults suffered from coronary artery disease in 2020. This increasing disease burden continues to fuel demand for advanced interventional cardiology devices.

COVID-19 Impact

The COVID-19 pandemic negatively impacted the market in 2020 due to postponement of elective cardiac procedures. Hospitals prioritized COVID-19 cases, delaying coronary and structural heart treatments. However, substantial recovery was observed in 2021 as elective and interventional procedures resumed globally. Post-pandemic, healthcare professionals increasingly prefer minimally invasive interventional procedures due to shorter hospital stays, faster recovery, and better infection control, supporting long-term market expansion.

Market Trends

Shifting Preference Toward Minimally Invasive Procedures

The growing preference for minimally invasive cardiac procedures is a key trend. These procedures offer reduced complications, shorter hospital stays, minimal incisions, and faster patient recovery.

According to the American Heart Association, approximately 1.5 million cardiac surgeries are performed globally each year. In the U.S. alone, nearly 900,000 Percutaneous Coronary Interventions (PCIs) are performed annually.

Reimbursement expansion has further strengthened adoption. In 2020, the Centers for Medicare & Medicaid Services announced reimbursement coverage for PCI procedures in Ambulatory Surgical Centers (ASCs) and Office-Based Labs (OBLs), accelerating procedural volumes outside hospital settings.

Market Growth Drivers

Rising Cardiovascular Disease Burden

Increasing environmental risk factors such as pollution, smoking, alcohol consumption, sedentary lifestyles, and unhealthy diets are contributing to the global rise in cardiovascular diseases. According to the American College of Cardiology, cardiovascular-related deaths in Asia increased from 5.6 million in 1990 to 10.8 million in 2019.

Product Launches and Strategic Collaborations

Major players are actively investing in R&D and launching innovative devices to meet growing demand. For instance, in July 2021, Medtronic launched the Prevail Drug-Coated Balloon (DCB) catheter in Europe for PCI procedures. Similarly, companies are engaging in partnerships, acquisitions, and regulatory approvals to strengthen product portfolios across emerging economies such as China and India.

Restraining Factors

Despite strong growth prospects, product recalls and regulatory scrutiny pose challenges. In July 2023, Abbott issued a recall for a cardiac catheter used in left atrial appendage occlusion due to safety concerns. Additionally, complications such as hematoma, vascular injury, and radial artery occlusion may limit device adoption. Strict regulatory approval processes also slow new product commercialization.

Segmentation Analysis

By Product

The market is segmented into coronary stents, structural heart devices, angioplasty balloons, catheters, embolic protection devices, and others.

• Coronary stents dominated the market with a 38.55% share in 2025, driven by high procedural volumes and government-led procurement programs in countries like China.
• Structural heart devices are projected to grow at a higher CAGR due to rising Transcatheter Aortic Valve Replacement (TAVR) procedures.
• Angioplasty balloons are also expected to witness substantial growth.

By End User

• Hospitals & Ambulatory Surgical Centers (ASCs) accounted for 66.21% share in 2026, owing to rising hospital admissions and procedure volumes.
• Catheterization labs & others are projected to grow moderately with expanding infrastructure globally.

Regional Insights

North America

North America generated USD 6.05 billion in 2025 and continues to dominate due to strong reimbursement policies and technological advancements. The U.S. market is projected to reach USD 6.18 billion by 2026.

Europe

Europe holds a significant share driven by affordable device pricing and rising regulatory approvals. The UK market is projected to reach USD 0.68 billion by 2026, while Germany is expected to reach USD 1.52 billion by 2026.

Asia Pacific

Asia Pacific is projected to register the highest CAGR during 2025-2034 due to expanding patient pools and domestic manufacturing growth. China is projected to reach USD 0.98 billion by 2026, Japan USD 0.47 billion, and India USD 0.79 billion.

Competitive Landscape

Prominent companies operating in the market include Edwards Lifesciences, Boston Scientific Corporation, Abbott, Medtronic, BIOTRONIK SE & Co. KG, Terumo Corporation, and B. Braun SE. These companies are focusing on product innovation, acquisitions, regulatory approvals, and geographic expansion to strengthen their global footprint.

Conclusion

The global interventional cardiology devices market is set for robust growth from USD 17.86 billion in 2025 to USD 34.01 billion by 2034, supported by the rising burden of cardiovascular diseases, increasing preference for minimally invasive procedures, expanding reimbursement coverage, and continuous technological advancements. While product recalls and regulatory challenges may restrain short-term growth, sustained innovation, strategic partnerships, and expanding healthcare infrastructure-especially in Asia Pacific-will ensure strong long-term market expansion through 2034.

Unit CAGR of 7.50% from 2026-2034

Segmentation By Product

• Coronary Stents
  • Bare-metal Stent (BMS)
  • Drug-eluting Stent (DES)
  • Others
• Structural Heart Devices
  • Heart Valves
  • Occluders & Others
• Angioplasty Balloons
• Catheters
  • Diagnostic Catheters
• Angiography
• IVUS
• Others
  • Treatment Catheters
• Atherectomy
• Thrombectomy
• Ablation
• Others
• Embolic Protection Devices
• Others

By End User

• Hospitals & ASCs
• Catheterization Labs & Others

By Region

• North America (By Product, End User, and Country)
  • U.S.
  • Canada
• Europe (By Product, End User, and Country/Sub-region)
  • Germany
  • France
  • U.K.
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Product, End User, and Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, End User, and Country/Sub-region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (By Product, End User, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Cardiovascular Diseases, By Key Countries/ Region, 2023/2025
• 4.2. Incidence of Atrial Fibrillation, By Key Countries/ Region, 2023/2025
• 4.3. Epidemiology: Stroke, By Key Countries/ Region, 2023/2025
• 4.4. Number of Percutaneous Coronary Interventions Procedures, By Key Countries, 2023/2025
• 4.5. New Product Launches, By Key Players
• 4.6. Key Industry Developments - Mergers, Acquisition, and Partnerships
• 4.7. Impact of COVID-19 on the Market

5. Global Interventional Cardiology Devices Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Coronary Stents
    • 5.1.1.1. Bare-metal Stent (BMS)
    • 5.1.1.2. Drug-eluting Stent (DES)
    • 5.1.1.3. Others
  • 5.1.2. Structural Heart Devices
    • 5.1.2.1. Heart Valves
    • 5.1.2.2. Occluders & Others
  • 5.1.3. Angioplasty Balloons
  • 5.1.4. Catheters
    • 5.1.4.1. Diagnostic Catheters
      • 5.1.4.1.1. Angiography
      • 5.1.4.1.2. IVUS
      • 5.1.4.1.3. Others
    • 5.1.4.2. Treatment Catheters
      • 5.1.4.2.1. Atherectomy
      • 5.1.4.2.2. Thrombectomy
      • 5.1.4.2.3. Ablation
      • 5.1.4.2.4. Others
  • 5.1.5. Embolic Protection Devices
  • 5.1.6. Others
• 5.2. Market Analysis, Insights and Forecast - By End User
  • 5.2.1. Hospitals & ASCs
  • 5.2.2. Catheterization Labs & Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East and Africa

6. North America Interventional Cardiology Devices Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Coronary Stents
    • 6.1.1.1. Bare-metal Stent (BMS)
    • 6.1.1.2. Drug-eluting Stent (DES)
    • 6.1.1.3. Others
  • 6.1.2. Structural Heart Devices
    • 6.1.2.1. Heart Valves
    • 6.1.2.2. Occluders & Others
  • 6.1.3. Angioplasty Balloons
  • 6.1.4. Catheters
    • 6.1.4.1. Diagnostic Catheters
      • 6.1.4.1.1. Angiography
      • 6.1.4.1.2. IVUS
      • 6.1.4.1.3. Others
    • 6.1.4.2. Treatment Catheters
      • 6.1.4.2.1. Atherectomy
      • 6.1.4.2.2. Thrombectomy
      • 6.1.4.2.3. Ablation
      • 6.1.4.2.4. Others
  • 6.1.5. Embolic Protection Devices
  • 6.1.6. Others
• 6.2. Market Analysis, Insights and Forecast - By End User
  • 6.2.1. Hospitals & ASCs
  • 6.2.2. Catheterization Labs & Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Interventional Cardiology Devices Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Coronary Stents
    • 7.1.1.1. Bare-metal Stent (BMS)
    • 7.1.1.2. Drug-eluting Stent (DES)
    • 7.1.1.3. Others
  • 7.1.2. Structural Heart Devices
    • 7.1.2.1. Heart Valves
    • 7.1.2.2. Occluders & Others
  • 7.1.3. Angioplasty Balloons
  • 7.1.4. Catheters
    • 7.1.4.1. Diagnostic Catheters
      • 7.1.4.1.1. Angiography
      • 7.1.4.1.2. IVUS
      • 7.1.4.1.3. Others
    • 7.1.4.2. Treatment Catheters
      • 7.1.4.2.1. Atherectomy
      • 7.1.4.2.2. Thrombectomy
      • 7.1.4.2.3. Ablation
      • 7.1.4.2.4. Others
  • 7.1.5. Embolic Protection Devices
  • 7.1.6. Others
• 7.2. Market Analysis, Insights and Forecast - By End User
  • 7.2.1. Hospitals & ASCs
  • 7.2.2. Catheterization Labs & Others
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. Germany
  • 7.3.2. Spain
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. U.K.
  • 7.3.6. Rest of Europe

8. Asia Pacific Interventional Cardiology Devices Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Coronary Stents
    • 8.1.1.1. Bare-metal Stent (BMS)
    • 8.1.1.2. Drug-eluting Stent (DES)
    • 8.1.1.3. Others
  • 8.1.2. Structural Heart Devices
    • 8.1.2.1. Heart Valves
    • 8.1.2.2. Occluders & Others
  • 8.1.3. Angioplasty Balloons
  • 8.1.4. Catheters
    • 8.1.4.1. Diagnostic Catheters
      • 8.1.4.1.1. Angiography
      • 8.1.4.1.2. IVUS
      • 8.1.4.1.3. Others
    • 8.1.4.2. Treatment Catheters
      • 8.1.4.2.1. Atherectomy
      • 8.1.4.2.2. Thrombectomy
      • 8.1.4.2.3. Ablation
      • 8.1.4.2.4. Others
  • 8.1.5. Embolic Protection Devices
  • 8.1.6. Others
• 8.2. Market Analysis, Insights and Forecast - By End User
  • 8.2.1. Hospitals & ASCs
  • 8.2.2. Catheterization Labs & Others
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. China
  • 8.3.2. India
  • 8.3.3. Japan
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Interventional Cardiology Devices Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Coronary Stents
    • 9.1.1.1. Bare-metal Stent (BMS)
    • 9.1.1.2. Drug-eluting Stent (DES)
    • 9.1.1.3. Others
  • 9.1.2. Structural Heart Devices
    • 9.1.2.1. Heart Valves
    • 9.1.2.2. Occluders & Others
  • 9.1.3. Angioplasty Balloons
  • 9.1.4. Catheters
    • 9.1.4.1. Diagnostic Catheters
      • 9.1.4.1.1. Angiography
      • 9.1.4.1.2. IVUS
      • 9.1.4.1.3. Others
    • 9.1.4.2. Treatment Catheters
      • 9.1.4.2.1. Atherectomy
      • 9.1.4.2.2. Thrombectomy
      • 9.1.4.2.3. Ablation
      • 9.1.4.2.4. Others
  • 9.1.5. Embolic Protection Devices
  • 9.1.6. Others
• 9.2. Market Analysis, Insights and Forecast - By End User
  • 9.2.1. Hospitals & ASCs
  • 9.2.2. Catheterization Labs & Others
• 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.3.1. Mexico
  • 9.3.2. Brazil
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Interventional Cardiology Devices Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Coronary Stents
    • 10.1.1.1. Bare-metal Stent (BMS)
    • 10.1.1.2. Drug-eluting Stent (DES)
    • 10.1.1.3. Others
  • 10.1.2. Structural Heart Devices
    • 10.1.2.1. Heart Valves
    • 10.1.2.2. Occluders & Others
  • 10.1.3. Angioplasty Balloons
  • 10.1.4. Catheters
    • 10.1.4.1. Diagnostic Catheters
      • 10.1.4.1.1. Angiography
      • 10.1.4.1.2. IVUS
      • 10.1.4.1.3. Others
    • 10.1.4.2. Treatment Catheters
      • 10.1.4.2.1. Atherectomy
      • 10.1.4.2.2. Thrombectomy
      • 10.1.4.2.3. Ablation
      • 10.1.4.2.4. Others
  • 10.1.5. Embolic Protection Devices
  • 10.1.6. Others
• 10.2. Market Analysis, Insights and Forecast - By End User
  • 10.2.1. Hospitals & ASCs
  • 10.2.2. Catheterization Labs & Others
• 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Boston Scientific Corporation
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Abbott
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Medtronic
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. BIOTRONIK SE & Co. KG
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. iVascular
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Terumo Corporation
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Teleflex Incorporated
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. B. Braun SE
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Alvimedica
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Biosensors International Group, Ltd
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)